Literature DB >> 30809038

Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival.

Grant Chappell1, Marcus Geer2, Erin Gatza1, Thomas Braun3, Tracey Churay1, Joseph Brisson1, Dale Bixby2, Bernard Marini4, Anthony Perissinotti4, David Frame4, Brian Parkin2, Pavan Reddy2, John Magenau2, Sung Won Choi5.   

Abstract

Entities:  

Year:  2019        PMID： 30809038     DOI： 10.1038/s41409-019-0493-5

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  5 in total

1.  Anti-FLT3 nanoparticles for acute myeloid leukemia: Preclinical pharmacology and pharmacokinetics.

Authors:  Mincheol Park; Vijaya Pooja Vaikari; Albert T Lam; Yong Zhang; John Andrew MacKay; Houda Alachkar
Journal:  J Control Release       Date:  2020-05-16       Impact factor: 9.776

2.  How I treat relapsed or refractory AML.

Authors:  Susan DeWolf; Martin S Tallman
Journal:  Blood       Date:  2020-08-27       Impact factor: 22.113

3.  Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era.

Authors:  Sujin Choi; Bo Kyung Kim; Hong Yul Ahn; Kyung Taek Hong; Jung Yoon Choi; Hee Young Shin; Hyoung Jin Kang
Journal:  Blood Res       Date:  2020-12-31

4.  Electronic Medical Record Search Engine (EMERSE): An Information Retrieval Tool for Supporting Cancer Research.

Authors:  David A Hanauer; Jill S Barnholtz-Sloan; Mark F Beno; Guilherme Del Fiol; Eric B Durbin; Oksana Gologorskaya; Daniel Harris; Brett Harnett; Kensaku Kawamoto; Benjamin May; Eric Meeks; Emily Pfaff; Janie Weiss; Kai Zheng
Journal:  JCO Clin Cancer Inform       Date:  2020-05

Review 5.  Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Wei Shi; Weiwei Jin; Linghui Xia; Yu Hu
Journal:  Acta Pharm Sin B       Date:  2020-06-30       Impact factor: 11.413
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.